Tirzepatide 2.5 mg: what the starter dose is really for

What the evidence says about starting at 2.5 mg

NICE's appraisal of tirzepatide (TA1026, published December 2024) draws on the SURMOUNT-1 trial, in which 2,539 adults with obesity received tirzepatide over 72 weeks. The impressive weight-loss figures from that trial (around 20–21% average reduction at the 15 mg dose) were achieved after a structured titration that began at 2.5 mg. No participant was handed a 15 mg pen on day one. The starting dose is, in that sense, built into the evidence base: the trial results only mean what they mean because of the ramp that preceded them.

The medicine's dual mechanism (activating both GIP and GLP-1 receptors) begins at 2.5 mg, but the appetite-suppressing and gastric-emptying effects are substantially more pronounced at higher maintenance doses. Gastrointestinal side effects such as nausea, loose stools and indigestion are most common after starting or increasing a dose; the 2.5 mg phase is deliberately gentle to reduce that likelihood. Most people find symptoms settle within a week or two. You can read the full patient-level detail on the NHS tirzepatide medicines page.

It is also worth knowing that 2.5 mg is not a dose unique to weight management: the same starting strength applies when tirzepatide is used for type 2 diabetes. The body makes no clinical distinction, the tolerance-building rationale is identical either way. If you want to understand exactly what the 1 mg tirzepatide strength involves before the licensed schedule begins, that page explains where it fits in the broader dosing picture. If you are curious about how the full dose schedule unfolds from here, the tirzepatide dose guide covers the titration pathway in detail.

Why staying on 2.5 mg longer than four weeks is not typically the plan

Occasionally people ask whether they can remain on 2.5 mg indefinitely if it feels comfortable. The short answer is that the licensed schedule does not support it as an ongoing maintenance dose, and a prescriber is unlikely to continue it beyond the starter period without a specific clinical reason. The therapeutic window for weight management sits higher up the dose ladder, 5 mg, 7.5 mg, and above. The 2.5 mg period is the runway, not the cruise altitude.

That said, there is no rigid countdown. If you are experiencing significant side effects at the starting dose, a prescriber can hold the titration until you have settled. Clinical judgement governs timing, not a calendar. The next step up to 5 mg usually happens at around week five, but that decision sits with your prescriber after reviewing how you have responded.

One practical note: if your first pen arrives on a Friday or just before a bank holiday, take it when you have a couple of low-key days ahead. The first week can involve some nausea, and starting mid-week (or timing it around a Monday delivery if you ordered the previous Thursday) gives your body the quieter days it sometimes needs to adjust. Minor planning, but patients who think ahead tend to find the transition smoother.

Who the licensed eligibility criteria actually cover at this dose

The 2.5 mg pen is the entry point for any adult starting tirzepatide, regardless of their starting weight or comorbidities. The private licensed eligibility for tirzepatide covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. A prescriber assesses the whole clinical picture; BMI alone does not settle the question. Lower thresholds apply for some ethnic backgrounds under UK guidance.

NICE's recommendation under TA1026 sets a higher bar for NHS access (BMI 35 or above with at least one qualifying comorbidity) and the NHS rollout is phased, so many people who would benefit clinically are not yet eligible on the NHS. For context on what private treatment costs and what that includes, the Mounjaro pricing page lays out the market picture honestly.

Tirzepatide is not licensed for people under 18, and it is not recommended during pregnancy, breastfeeding or while trying to conceive. A history of certain conditions, including medullary thyroid carcinoma or pancreatitis, requires careful prescriber discussion before starting. The Mounjaro overview covers contraindications in full.

What happens after the 2.5 mg phase

The four-week starter period ends with a prescriber review. At nume (sorry, at the service level) every repeat order is clinically re-assessed by a GPhC-registered Independent Prescriber before dispatch. Dose increases are not automatic. Evidence of tolerance and, for higher steps, evidence of response is reviewed before the next pen is approved. A prescriber considers your reported side effects, any changes in health, and whether the current dose is appropriate to continue or increase.

After 2.5 mg the typical next step is 5 mg, and the titration can continue through 7.5, 10, 12.5 and up to 15 mg. The 10 mg dose page covers what the evidence shows at that level. If you are researching the full picture before starting, the weight-loss treatment overview sets out how tirzepatide fits alongside lifestyle changes. Our clinical team reviews every consultation personally, questions about your specific situation are exactly what that process is for.

When you are ready to find out whether tirzepatide is clinically appropriate for you, speak to our prescribers through a free consultation. No waiting list, no algorithm.